Opinion|Videos|October 7, 2024
Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD
Key Takeaways
- Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
- Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with a favorable safety profile.
Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Biologic Therapy Linked to Lower 10-Year MACE Risk Across Racial Groups in Psoriasis
2
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer
3
Body Weight, Not BMI, Associated With Brodalumab Response Trajectory in Plaque Psoriasis
4
Journal Digest: September 9, 2026
5